In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37399559.
- Also identified by DOI 10.7326/J23-0048.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. <b>Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.</b> Lancet. 2023;401:1159-1171. 36871574.
Medical subject headings
- Colitis, Ulcerative